ArticleClinical journal of the American Society of Nephrology : CJASN2026
The Effect of Gender-Affirming Hormone Treatment on Kidney Function Trajectories in Transgender and Gender-Diverse Veterans.
Article in Clinical journal of the American Society of Nephrology : CJASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond the Binary: A Holistic Perspective on Gender-Affirming Hormone Therapy and Measures of Kidney Health.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
key pointsAdministration of testosterone was associated with decline in the slope of eGFR in transgender veterans. Administration of testosterone was associated with increase in creatinine in first 12 months of hormone initiation in transgender veterans. Administration of estrogen was associated with stability of eGFR slope in transgender veterans.
backgroundThe impact of hormone therapy (HT) on kidney function in transgender and gender-diverse (TGD) individuals remains poorly understood, and this lack of data poses challenges in caring for TGD individuals with kidney disease. The aim of this study was to compare serum creatinine levels and eGFR slope, a critical marker of kidney function, in transgender women (TW) and transgender men (TM) relative to cisgender (non-TGD) controls.
methodsWe conducted a longitudinal cohort study of veterans using Veterans Health Administration care from January 2006 to December 2019. Serum creatinine and eGFR were assessed using algorithms based on affirmed gender and sex assigned at birth. Within-group changes over time were assessed using generalized linear mixed-effect models with random intercept and time modeled as a categorical variable. Two-way fixed-effects models were used to assess changes in eGFR slopes relative to HT initiation compared with cisgender controls.
resultsThe analytic dataset included 6616 veterans of whom 262 were receiving HT (214 [3%] TW and 48 [0.72%] TM) and 6354 were cisgender not receiving HT (1988 [30%] cisgender women and 4366 [66%] cisgender men). Serum creatinine was higher as early as 3 months after HT initiation in TM veterans with stabilization by 12 months, whereas TW veterans did not demonstrate any significant change in their serum creatinine. eGFR was significantly lower in TM veterans after HT initiation, whereas it remained stable in TW veterans.
conclusionsOur findings suggest that HT is associated with divergent effects on kidney function. These findings suggest the need for individualized kidney monitoring and potentially refined eGFR calculations for TGD populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.